Civeo Corp
F:44C1
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Civeo Corp
F:44C1
|
US |
|
I
|
Innate Pharma SA
XBER:IDD
|
FR |
|
P
|
PPC Ltd
JSE:PPC
|
ZA |
|
D
|
Dexcom Inc
F:DC4
|
US |
|
C
|
Capita PLC
XMUN:CTAA
|
UK |
|
O
|
Outlook Therapeutics Inc
F:41ON
|
US |
|
M
|
Mandom Corp
F:MD9
|
JP |
|
Innate Pharma SA
F:IDD
|
FR |
|
BYD Co Ltd
F:BY6A
|
CN |
|
L
|
L'Air Liquide Societe Anonyme pour l'Etude et l'Exploitation des Procedes Georges Claude SA
XMUN:AIL
|
FR |
|
Fuji Kyuko Co Ltd
F:8V7
|
JP |
|
Far East Hospitality Trust
OTC:FEHTF
|
SG |
|
T
|
Teekay Tankers Ltd
F:3TKA
|
CA |
|
Innate Pharma SA
PAR:IPH
|
FR |
Wall St Price Targets
44C1 Price Targets Summary
Civeo Corp
According to Wall Street analysts, the average 1-year price target for 44C1 is 21.88 EUR with a low forecast of 20.75 EUR and a high forecast of 23.48 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is 44C1's stock price target?
Price Target
21.88
EUR
According to Wall Street analysts, the average 1-year price target for 44C1 is 21.88 EUR with a low forecast of 20.75 EUR and a high forecast of 23.48 EUR.
What is the Revenue forecast for Civeo Corp?
Projected CAGR
3%
Over the last 14 years, the compound annual growth rate for Revenue has been -2%. The projected CAGR for the next 7 years is 3%.
What is the Operating Income forecast for Civeo Corp?
Projected CAGR
22%
Over the last 14 years, the compound annual growth rate for Operating Income has been -25%. The projected CAGR for the next 7 years is 22%.
